DNTH DIANTHUS THERAPEUTICS INC revenue, earnings and financials

For the quarter ended June 30, 2026, DIANTHUS THERAPEUTICS INC reported revenue of n/a, net income of −$50.2M and diluted EPS of −$0.90; for the fiscal year ended December 2025 revenue was $2.04M, down 67.3% on the year before.

DNTH annual revenue and earnings

• Fiscal year ended Dec 2025: revenue $2.04M, gross profit n/a, operating income −$178M, net income −$162M (margin -7973.3%), EPS −$4.20
• Fiscal year ended Dec 2024: revenue $6.24M, gross profit n/a, operating income −$102M, net income −$85.0M (margin -1362.8%), EPS −$2.55
• Fiscal year ended Dec 2023: revenue $2.83M, gross profit n/a, operating income −$48.2M, net income −$43.5M (margin -1540.9%), EPS −$8.45
• Fiscal year ended Dec 2022: revenue $6.42M, gross profit n/a, operating income −$29.7M, net income −$28.5M (margin -443.8%), EPS −$32.57
• Fiscal year ended Dec 2021: revenue $1.48M, gross profit n/a, operating income −$13.1M, net income −$13.1M (margin -888.1%), EPS −$15.01

DNTH quarterly revenue and earnings

• Quarter ended Jun 30, 2026: revenue n/a, net income −$50.2M, EPS −$0.90
• Quarter ended Mar 31, 2026: revenue n/a, net income −$40.8M, EPS −$0.85
• Quarter ended Dec 31, 2025 (from the annual report): revenue $284K (down 78.6% year over year), net income −$64.4M, EPS −$1.53
• Quarter ended Sep 30, 2025: revenue $396K (down 81.8% year over year), net income −$36.8M, EPS −$0.97
• Quarter ended Jun 30, 2025: revenue $193K (down 89.6% year over year), net income −$31.6M, EPS −$0.88
• Quarter ended Mar 31, 2025: revenue $1.16M (up 33.1% year over year), net income −$29.5M, EPS −$0.82
• Quarter ended Dec 31, 2024 (from the annual report): revenue $1.33M, net income −$28.4M, EPS −$0.76
• Quarter ended Sep 30, 2024: revenue $2.17M (up 135.1% year over year), net income −$25.2M, EPS −$0.74
• Quarter ended Jun 30, 2024: revenue $1.86M, net income −$17.6M, EPS −$0.51
• Quarter ended Mar 31, 2024: revenue $874K, net income −$13.7M, EPS −$0.54
• Quarter ended Dec 31, 2023 (from the annual report): revenue n/a, net income −$10.6M, EPS $16.16
• Quarter ended Sep 30, 2023: revenue $924K (down 21.2% year over year), net income −$14.8M, EPS −$3.78
• Quarter ended Jun 30, 2023: revenue n/a, net income −$11.1M, EPS −$12.73
• Quarter ended Mar 31, 2023: revenue n/a, net income −$7.09M, EPS −$8.10
• Quarter ended Dec 31, 2022 (from the annual report): revenue n/a, net income −$10.1M, EPS −$22.99
• Quarter ended Sep 30, 2022: revenue $1.17M, net income −$7.78M, EPS −$8.90
• Quarter ended Jun 30, 2022: revenue n/a, net income −$5.70M, EPS −$0.29
• Quarter ended Mar 31, 2022: revenue n/a, net income −$4.88M, EPS −$0.39
• Quarter ended Dec 31, 2021 (from the annual report): revenue n/a, net income $38.7M, EPS −$14.03
• Quarter ended Sep 30, 2021: revenue n/a, net income −$17.4M, EPS −$0.30

DNTH cash flow, buybacks and dividends

• Fiscal year ended Dec 2025: operating cash flow −$129M, share buybacks n/a, dividends $0.00 per share
• Fiscal year ended Dec 2024: operating cash flow −$78.2M, share buybacks n/a, dividends $0.00 per share
• Fiscal year ended Dec 2023: operating cash flow −$36.9M, share buybacks n/a, dividends $0.00 per share
• Fiscal year ended Dec 2022: operating cash flow −$29.1M, share buybacks n/a
• Fiscal year ended Dec 2021: operating cash flow −$9.90M, share buybacks n/a

DNTH balance sheet

• Jun 30, 2026: cash $111M, total assets $1.21B, total liabilities $41.2M, shareholders' equity $1.17B
• Mar 31, 2026: cash $628M, total assets $1.25B, total liabilities $45.6M, shareholders' equity $1.20B
• Dec 31, 2025: cash $51.1M, total assets $531M, total liabilities $37.5M, shareholders' equity $493M
• Sep 30, 2025: cash $56.0M, total assets $577M, total liabilities $31.0M, shareholders' equity $546M
• Jun 30, 2025: cash $13.2M, total assets $326M, total liabilities $23.0M, shareholders' equity $303M
• Mar 31, 2025: cash $10.1M, total assets $349M, total liabilities $20.0M, shareholders' equity $329M
• Dec 31, 2024: cash $22.8M, total assets $374M, total liabilities $21.5M, shareholders' equity $352M
• Sep 30, 2024: cash $33.7M, total assets $354M, total liabilities $16.4M, shareholders' equity $338M

What is DNTH's revenue?

DIANTHUS THERAPEUTICS INC reported $2.04M of revenue for the fiscal year ended December 2025.

Is DNTH profitable?

No. DIANTHUS THERAPEUTICS INC lost $192M over the last four quarters.

What is DNTH's EPS?

Diluted earnings per share over the last four quarters were −$4.25; −$0.90 in the latest quarter.

DNTH ownership and insider trades · All stocks